Celldex Therapeutics Surges 30% After Positive Phase 2 Data In Brain Cancer

Positive results in an interim phase 2 analysis of rindopepimut show increased survival.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.